Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7485641 | 0.91 | TSHR (0.35) | TSHRSMN1; SMN2 | |
| SCHEMBL5098802 | 0.83 | CTSK (0.37) | TSHR | |
| SCHEMBL5098738 | 0.81 | CACNA1B (0.39) | TSHRSMN1; SMN2 | |
| SCHEMBL5092592 | 0.81 | LMNA (0.36) | SMN1; SMN2 | |
| SCHEMBL5098778 | 0.80 | CYP2C19 (0.44) | SMN1; SMN2 | |
| SCHEMBL4693518 | 0.80 | CTSK (0.41) | SMN1; SMN2 | |
| SCHEMBL7485646 | 0.80 | TSHR (0.36) | TSHRSMN1; SMN2 | |
| SCHEMBL5105397 | 0.80 | ALDH1A1 (0.42) | TSHRSMN1; SMN2 | |
| SCHEMBL5096610 | 0.79 | GAA (0.39) | TSHRSMN1; SMN2 | |
| SCHEMBL5092485 | 0.79 | TP53 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7405209-B2 | e.g. 2-Benzyloxycarbonylamino-4-methyl-pentanoyl)-3-oxo-azepan-4-ylcarbamoyl}carbamic acid benzyl ester; protease inhibitors like cathepsin K; osteoporosis, osteo- and rheumatoid arthritis and periodontal disease; inhibiting excessive cartilage or matrix degradation | SMITHKLINE BEECHAM CORPORATION (US) | 2008-07-29 | — | — | US | disclosed |
| EP-1307204-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2004-06-02 | — | — | EP | disclosed |
| EP-1384713-A1 | 4-amino-azepan-3-one derivatives as protease inhibitors | SmithKline Beecham Corporation (US) | 2004-01-28 | — | — | EP | disclosed |
| US-20040002487-A1 | Protease inhibitors | MARQUIS ROBERT WELLS (US) | 2004-01-01 | — | — | US | disclosed |
| US-20030225061-A1 | Protease inhibitors | MARQUIS ROBERT WELLS (US) | 2003-12-04 | — | — | US | disclosed |
| US-20030144175-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2003-07-31 | — | — | US | disclosed |
| EP-1307204-A1 | PROTEASE INHIBITORS | SmithKline Beecham Corporation (US) | 2003-05-07 | — | — | EP | disclosed |
| US-20020147188-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-10-10 | — | — | US | disclosed |
| WO-2001095911-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225061-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | TSHR 4016/4885SMN1; SMN2 4669/4885 |
| US-20020147188-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | TSHR 4016/4885SMN1; SMN2 4669/4885 |
| US-20040002487-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | TSHR 4016/4885SMN1; SMN2 4669/4885 |
| US-20030144175-A1 | Protease inhibitors | CTSK, MMP13, CTSZ | TSHR 4016/4885SMN1; SMN2 4669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.